Drug Profile

Epoetin beta biosimilar - CinnaGen

Alternative Names: Beta erythropoietin; CinnaPoietin; rec Hu-EPO beta; rec Hu-erythropoietin beta

Latest Information Update: 30 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CinnaGen
Class Antianaemics; Colony-stimulating factors; Recombinant erythropoietins
Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Anaemia

Most Recent Events

19 Jul 2017 CinnaGen completes a phase III trial for Anaemia in Iran (SC) (IV) (IRCT201601156135N6)
01 Mar 2016 CinnaGen initiates enrolment in a phase III trial for Anaemia in Iran (SC) (IV) (IRCT201601156135N6)
31 Dec 2013 Launched for Anaemia in Iran (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com